VEGFA and neoplasm: Because of their mode of action, the compounds that preferentially target post-transcriptional regulatory processes found in tumor cells, or under other conditions of cellular stress, to reduce VEGF production may have a selective efficacy advantage over therapies that act downstream by sequestering ligand or blocking receptor activation.